On January 31, 2022, Balboa Ramilo, Amanda; Becirovic-Agic, Mediha; Petri, Marcelo Heron; Mani, Kevin; Wanhainen, Anders; Waagsaeter, Dick published an article.SDS of cas: 380843-75-4 The title of the article was The tyrosine kinase inhibitor Bosutinib does not inhibit angiotensin II-induced abdominal aortic aneurysm: Validation of the importance of PDGFR and c-Kit tyrosine kinases by Imatinib. And the article contained the following:
Validation of the importance of PDGFR and c-Kit tyrosine kinases by imatinib. All experiments were approved by the Animal Experiments Ethical Committee in Uppsala. Mice were divided into four groups. One group of control mice (n =8) was infused with Ringer’s solution In the other three groups, aneurysm was induced by infusion of 1000 ng/kg/min of AngII. AngII-infused animals were treated with vehicle (n = 20), 10 mg/kg of Bosutinib (Bos, Cat.number S1014, Selleckchem, TX, USA) (n = 20) or 100 mg/kg of Bosutinib (n = 10) by oral gavage, for 22 days. Control animals also received vehicle by oral gavage. On the last day of the experiment, an abdominal ultrasound (Vevo 1100 ultrasound, VisualSonics) was performed for measurement of aortic diameter Control animals had an average aortic diameter of 1.2 ± 0.108 mm. Aneurysm was defned as an aortic diameter equal or superior to 1.8 mm (1.5-fold increase relative to control). These results indicate that treatment of AngII-induced mice with Bosutinib, in a similar dose to Imatinib or higher, does not have an effect on AAA development. This confirms that inhibition of the PDGFR and/or c-Kit is necessary for the effect of Imatinib on abdominal aortic aneurysm development. Thus, drugs inhibiting c-Kit and PDGFR should be of more interest to test in the context of abdominal aortic aneurysm. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).SDS of cas: 380843-75-4
The Article related to abdominal aortic aneurysm pdgfr ckit tyrosine kinase imatinib, aneurysm, inhibitor, rupture, tyrosine kinase, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.SDS of cas: 380843-75-4
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics